Ticker LaunchReverse merger · Pending · EOSX
Eos SENOLYTIX, Inc.
Reverse merger with Pulmatrix, Inc. (PULM)
Eos SENOLYTIX, Inc. agreed to merge into Pulmatrix, Inc. (PULM), a Nasdaq-listed clinical-stage respiratory biotech, in a reverse merger that takes the private company public. The deal was announced on Mar 26, 2026. The combined company is expected to trade as Eos SENOLYTIX, Inc. (EOSX) on Nasdaq.
Eos SENOLYTIX is a biotechnology company developing gerotherapeutic peptides that target mitochondrial dysfunction in aging-related diseases. Its lead clinical candidate, PTC-2105, is aimed at sarcopenia and sarcopenic obesity.
- Status
- Pending
- Private company
- Eos SENOLYTIX, Inc.
- Public company
- Pulmatrix, Inc. (PULM)
- Public company business before
- Nasdaq-listed clinical-stage respiratory biotech
- Announced
- Mar 26, 2026
- Combined company
- Eos SENOLYTIX, Inc. (EOSX)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- 8-K merger agreement announcement Mar 27, 2026
- Press release Mar 26, 2026
- DEFM14A (registration/proxy) Sep 25, 2026
- All filings on EDGAR CIK 1574235
Other pending reverse mergers
- Fortitude Mining Holdings, Inc. (Fortitude Mining HoldCo, LLC)into HeartSciences Inc. · Jun 23, 2026
- Serapha Bio, Inc.into Boundless Bio, Inc. · Jun 22, 2026
- Avenzo Therapeutics, Inc.into Rallybio Corporation · Jun 1, 2026
- Mentari Therapeutics, Inc.into InMed Pharmaceuticals Inc. · May 19, 2026
- Gravitics, Inc.into Non-Invasive Monitoring Systems, Inc. · Mar 6, 2026
- Thramann Holdings, LT350, Influence Healthcare, Voyexinto Auddia Inc. · Feb 17, 2026